Alalevonadifloxacin
Chemical compound
- Rx in India
- (12S)-8-[4-[(2S)-2-Aminopropanoyl]oxypiperidin-1-yl]-7-fluoro-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid
- 706809-20-3
- 16734914
- 10756
- 19538972
- 57B7E1D1TG
- ChEMBL5095635
- Interactive image
- C[C@H]1CCC2=C3N1C=C(C(=O)C3=CC(=C2N4CCC(CC4)OC(=O)[C@H](C)N)F)C(=O)O
InChI
- InChI=InChI=1S/C22H26FN3O5/c1-11-3-4-14-18-15(20(27)16(21(28)29)10-26(11)18)9-17(23)19(14)25-7-5-13(6-8-25)31-22(30)12(2)24/h9-13H,3-8,24H2,1-2H3,(H,28,29)/t11-,12-/m0/s1
- Key:OUXXDXXQNWKOIF-RYUDHWBXSA-N
Alalevonadifloxacin (trade name Emrok O) is an antibiotic of the fluoroquinolone class.[1] It is a prodrug of levonadifloxacin with increased oral bioavailability.[2] In India, it is approved for the treatment of infections with Gram-positive bacteria.[3]
References
- ^ Saseedharan S, Dubey D, Singh RK, Zirpe K, Choudhuri AH, Mukherjee DN, et al. (2024). "Treatment challenges in the management of difficult-to-treat gram-positive infections: A consensus view apropos therapeutic role of novel anti-MRSA antibiotics, levonadifloxacin (IV) and alalevonadifloxacin (oral)". Indian Journal of Medical Microbiology. 47: 100528. doi:10.1016/j.ijmmb.2024.100528. PMID 38228227.
- ^ Bhawsar S, Kale R, Deshpande P, Yeole R, Bhagwat S, Patel M (December 2021). "Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection". Bioorganic & Medicinal Chemistry Letters. 54: 128432. doi:10.1016/j.bmcl.2021.128432. PMID 34757217.
- ^ "Alalevonadifloxacin". AdisInsight. Springer Nature Switzerland AG.
- v
- t
- e
(inhibit bacterial
purine metabolism,
thereby inhibiting
DNA and RNA
synthesis)
DHFR inhibitor | |||||||||
---|---|---|---|---|---|---|---|---|---|
Sulfonamides (DHPS inhibitor) |
| ||||||||
Combinations |
| ||||||||
Other DHPS inhibitors |
(inhibit bacterial
topoisomerase
and/or DNA gyrase,
thereby inhibiting
DNA replication)
1st generation | |
---|---|
Fluoroquinolones | |
Newer non-fluorinated | |
Related (DG) |
inhibitors
Nitroimidazole derivatives |
---|
Rifamycins/ RNA polymerase | |
---|---|
Lipiarmycins |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e